Halozyme Therapeutics (NASDAQ:HALO) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $68.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Finally, Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $47.99 on Monday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The business’s 50-day simple moving average is $50.28 and its two-hundred day simple moving average is $54.07. The stock has a market cap of $6.11 billion, a PE ratio of 15.89, a P/E/G ratio of 0.44 and a beta of 1.23.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently bought and sold shares of HALO. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the second quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $49,000. GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth $65,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.